# PDC Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pdc-biotech

- Industry: Pharmaceuticals
- Headquarters: Vienna, Austria
- Website: www.pdcbiotech.com
- Total disclosed funding: $6M
- Latest round: Series A (Oct 30, 2009)
- Investors on record: 2

## About

PDC Biotech GmbH is a biotechnology company focused on developing innovative therapies to address unmet medical needs, particularly in the fields of immunotherapy and oncology.PDC Biotech GmbH operates out of Vienna, Austria, and specializes in biotechnology solutions. The company was co-led in a EUR 4 million Series A financing round by Edmond de Rothschild and MIG Fonds in October 2009. The founder's history and past ventures are not publicly documented.PDC Biotech GmbH specializes in a range of innovative biopharmaceutical products designed to address specific medical needs, particularly in immunotherapy and oncology. Their core offerings include therapeutic solutions that aim to enhance patient outcomes in complex diseases, ultimately benefiting healthcare providers and patients. These solutions are tailored for end users in the healthcare sector, aiming to streamline treatment protocols and improve efficacy. The company has launched its products in various geographical markets, facilitating a broader reach and adaptability across different patient needs. PDC Biotech GmbH emphasizes its commitment to quality and efficacy in its offerings.The company's revenue model primarily revolves around partnership agreements and product sales, facilitating ongoing engagement with healthcare providers and institutions. Typical transactions may involve licensing deals and direct sales, allowing clients to access their innovative therapeutic products with ease. For instance, clients may enter into annual contracts, ensuring that they receive continuous access to PDC Biotech's solutions. The financial framework is designed to promote long-term relationships with healthcare providers, fostering repeat engagement and loyalty. Overall, PDC Biotech GmbH’s approach to revenue generation emphasizes flexibility and adaptability to meet the evolving demands of the healthcare market.PDC Biotech GmbH is focused on expanding its product line with new therapeutic solutions aimed at enhancing treatment efficacy in immunotherapy. The company plans to target additional markets in Europe and North America by 2025. The recent EUR 4 million raised in the Series A funding round will be utilized to support the development of these new products and facilitate entry into these new markets, allowing PDC Biotech to strengthen its position in the global biotech landscape.

## Funding rounds

- Series A, Oct 30, 2009, $6M — Andera Partners, MIG Capital

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A
- MIG Capital (https://capitalatlas.ai/funds/mig-capital) — Series A